Effective atomic number and electron density from dual-energy CT for differentiating malignant gliomas: Validation using the World Health Organization 2021 brain tumor classification.

Masami Shirota, Masayuki Nitta, Ayako Yoshida, Syunichi Kouriyama, Taiichi Saitou, Syunsuke Tsuduki, Yoshihiro Muragaki, Takakazu Kawamata

Abstract readObservational StudyValidation Study

PubMed Full text at PMC Publisher

In one paragraph

Observational study in The neuroradiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masami ShirotaCentral Radiation Department, Tokyo Women's Medical University, Japan.ORCID 0009-0004-4439-6446

Masayuki NittaNeurosurgery, Tokyo Women's Medical University, Japan.

Ayako YoshidaCentral Radiation Department, Tokyo Women's Medical University, Japan.

Syunichi KouriyamaNeurosurgery, Tokyo Women's Medical University, Japan.

Taiichi SaitouNeurosurgery, Tokyo Women's Medical University, Japan.

Syunsuke TsudukiNeurosurgery, Tokyo Women's Medical University, Japan.

Yoshihiro MuragakiCenter for Advanced Medical Engineering Research and Development, Kobe University, Japan.

Takakazu KawamataNeurosurgery, Tokyo Women's Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the World Health Organization (WHO) 2021 brain tumor pathology classification, we evaluated the usefulness of dual-energy CT (DECT) for differentiating malignancy grades in malignant gliomas and examined its correlation with amide proton transfer (APT). A prospective observational study was conducted on 49 patients: 16 with glioblastoma (GBM, grade 4), 13 with astrocytoma (A3, grade 3), 10 with oligodendroglioma (O3, grade 3), and 10 with oligodendroglioma (O2, grade 2). Effective atomic number (Zeff) and electron density (ED) from DECT were analyzed for tumor grade differentiation and correlation with APT. High-grade gliomas, which are influenced by vascular endothelial growth factor (VEGF) and microvascular proliferation, showed significant differences and correlations in post-contrast Zeff. A correlation between Zeff and MIB-1 suggests its potential as an indicator of cell proliferation. Additionally, correlations between Zeff and APT, as well as between ED and APT, indicate that DECT may be useful for grading malignant gliomas.

Indexed as

Brain NeoplasmsGliomaTomography, X-Ray ComputedAdultAgedDiagnosis, DifferentialFemaleHumansMaleMiddle AgedNeoplasm GradingProspective StudiesWorld Health Organizationamide proton transfer imagingastrocytomaDual-energy CTeffective atomic numberelectron densityglioblastomaoligodendrogliomaWorld Health Organization 2021

Identifiers

PMID40991850

DOI10.1177/19714009251373068

PMCPMC12460291

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.